HPGC Renmintongtai Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Weidong Zhu

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	9.2yrs
CEO ownership	n/a
Management average tenure	2.2yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO

Weidong Zhu (54 yo)

9.2yrs

Tenure

CN¥1,002,900

Compensation

Mr. Weidong Zhu served as Deputy General Manager at HPGC Renmintongtai Pharmaceutical Corporation. Mr. Zhu serves as Deputy General Manager and General manager of Harbin Renmintongtai Pharmacy chain stores...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Weidong Zhu	GM & Director	no data	CN¥1.00m	no data
Cong Feng Gu	Deputy GM & Director	no data	CN¥891.20k	no data
Wang Lei	Board Secretary	2.2yrs	CN¥155.70k	no data
Ping Guan	Deputy GM & CFO	2.1yrs	no data	no data
Jin Wei Zhang	Chief Accountant	9.2yrs	CN¥176.80k	no data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 600829's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Weidong Zhu	GM & Director	9.2yrs	CN¥1.00m	no data
Cong Feng Gu	Deputy GM & Director	no data	CN¥891.20k	no data
Xiaodong Meng	Chairman of the Supervisory Board	1.8yrs	no data	no data
Bin Wu	Independent Director	4.8yrs	CN¥80.00k	no data
Bo Liu	Vice Chairman	1.8yrs	no data	no data
Guoren Lin	Chairman of the Board	1.8yrs	no data	no data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Board: 600829's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

HPGC Renmintongtai Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Recent updates

HPGC Renmintongtai Pharmaceutical Corporation to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2023 Results on Oct 25, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 27%

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in 2Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings released: EPS: CN¥0.45 (vs CN¥0.48 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.17 in 2Q 2021)

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.056 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.083 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.25 (vs CN¥0.46 in FY 2019)

New 90-day low: CN¥5.79

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2020 Results on Mar 20, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥6.62

New 90-day high: CN¥7.77

New 90-day low: CN¥7.10

Third quarter earnings released

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2020 Results on Oct 17, 2020

New 90-day low: CN¥7.28

Earnings released

New 90-day high - CN¥8.53

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2020 Results on Aug 15, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age